AstraZeneca shares climb after earnings beat estimates as cancer drug portfolio drives strong growth

AstraZeneca reported adjusted EPS of $2.63 for the latest quarter, up 21% year-on-year and ahead of analyst expectations, driven by robust demand for oncology medicines Enhertu and Imfinzi. Shares rose about 2% in London trade, though the stock is still down around 5.2% year-to-date. The company reaffirmed its full-year guidance and reiterated its $80 billion revenue target by 2030, while raising peak sales expectations for experimental COPD drug tozorakimab to above $5 billion.